» Articles » PMID: 4608945

Tumor Induction by Murine Sarcoma Virus in AKR and C58 Mice. Reduction of Tumor Regression Associated with Appearance of Gross Leukemia Virus Pseudotypes

Overview
Journal J Exp Med
Date 1974 Nov 1
PMID 4608945
Citations 2
Authors
Affiliations
Soon will be listed here.
Abstract

Adult AKR and C58 mice injected intramuscularly with murine sarcoma virus, Moloney isolate (M-MSV), developed high incidence of nonregressing local tumors. Histologically, these tumors revealed the typical pleomorphism of M-MSV sarcomas; in some cases, however, neoplastic tissue showed a nodular or diffuse growth of monomorphic myoblastlike cells, reminiscent of clonal aggregates. No depression of immune reactivity was found in M-MSV-injected mice as evaluated by direct hemolytic plaque-forming cells against SRBC and by virus-neutralizing antibody production. The MSV recovered from the induced tumors proved to be, by neutralization assay, a Gross (G)-MSV pseudotype. Moreover, tumor cell suspensions absorbed out cytotoxic antibody directed against G-cell surface antigens. Therefore, the conclusion was drawn that MSV with envelope characteristics of endogenous G leukemia virus had formed in vivo through a phenotypic mixing phenomenon. The failure of tumors to regress has been interpreted as mainly due to the partial unresponsiveness of host immune reactivity towards G-MuLV specified antigens. Since MSV-tumors arose in AKR mice after a very long latent period, the possibility was considered that this relative resistance might depend on immunologic mechanisms. In fact, M-MSV-injected AKR mice immunodepressed by goat antimouse lymphocyte serum or rendered partially tolerant by neonatal M-MuLV inoculation developed sarcomas with higher incidence and with a shorter latency. Furthermore, the MSV recovered from these early tumors proved to be the original Moloney pseudotype.

Citing Articles

Immunization against primary, transplanted and spontaneous murine leukaemia using a live Moloney sarcoma virus vaccine.

Mayer A, Basombrio M, Pasqualini C Br J Cancer. 1980; 41(6):966-75.

PMID: 6252923 PMC: 2010361. DOI: 10.1038/bjc.1980.175.


In vitro malignant progression of cells derived from Abelson murine leukaemia virus-induced thymic lymphomas.

Saggioro D, Zamarchi R, DAndrea E, Chieco-Bianchi L Br J Cancer. 1988; 58(2):152-7.

PMID: 3262364 PMC: 2246750. DOI: 10.1038/bjc.1988.183.

References
1.
Chan S, Hook W, Turner W, Chirigos M . Immunosuppression by murine sarcoma virus (Moloney). Infect Immun. 1970; 1(3):288-92. PMC: 415894. DOI: 10.1128/iai.1.3.288-292.1970. View

2.
Chieco-Bianchi L, Collavo D, Biasi G, Colombatti A . Prevention of murine sarcoma virus oncogenesis in offspring of immunized female mice. Br J Cancer. 1973; 28(3):238-44. PMC: 2008979. DOI: 10.1038/bjc.1973.143. View

3.
Geering G, Old L, Boyse E . Antigens of leukemias induced by naturally occurring murine leukemia virus: their relation to the antigens of gross virus and other murine leukemia viruses. J Exp Med. 1966; 124(4):753-72. PMC: 2138242. DOI: 10.1084/jem.124.4.753. View

4.
Old L, Boyse E, STOCKERT E . The G (Gross) leukemia antigen. Cancer Res. 1965; 25(6):813-9. View

5.
Temin H . Separation of morphological conversion and virus production in Rous sarcoma virus infection. Cold Spring Harb Symp Quant Biol. 1962; 27:407-14. DOI: 10.1101/sqb.1962.027.001.038. View